Nanomedicines for brain diseases

Published on November 29, 2018   50 min
Hello. I'm Giovanni Tosi. I'm an Associate Professor at the University of Modena and Reggio Emilia in the field of Pharmaceutical Sciences. I'm belonging to the Parliament of Life Science and my work is mainly devoted to nanomedicine and in particular to the application of nanomedicine in brain disease.
So, if you look at the last 10 years of nanomedicine for brain disease records, you will see that a very huge number of papers published in different international journals with skilled preclinical results mainly on therapeutics and diagnostics.
But, if you go to look how many are the nanomedicine products for brain disease markets, you will find absolutely nothing. So, it is the Death Valley of this nanomedicine approach.
So, there are many factors that will affect the marketability of nanomedicine for brain disease on marketing that are mainly dealing with safety, efficacy, GMP production, scaling up of nanomedicine, and there's a problem in economics sustainability. So, the question now is if the problem is connected with nanomedicine as nano-sized systems or the problem is connected with the targets that is the brain.